Lincoln Pharmaceuticals Limited has informed the Exchange about Credit Rating
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CRISIL has reaffirmed its credit ratings on Lincoln Pharmaceuticals' bank facilities worth Rs 102 crore. The long-term rating stays at 'CRISIL A/Stable' and the short-term rating at 'CRISIL A1'. The ratings reflect the company's established position in the pharmaceutical industry, strong promoter experience of over three decades, and a healthy financial profile. Revenue grew 14% year-on-year to Rs 623 crore in FY25, with nil debt and consolidated networth of Rs 671 crore. Weaknesses noted include working capital-intensive operations (170-185 days), regulatory risks, and sizeable loans and advances of Rs 141 crore extended to affiliates. CRISIL also revised its analytical approach to combine LPL with Zullinc Healthcare under the 'Lincoln group' for rating purposes.
This is a neutral-to-positive development for shareholders, as the rating has been maintained at investment grade (CRISIL A) with a stable outlook, signaling financial stability and continued lender confidence. Stock price impact is likely minimal since there is no rating change, but the strong balance sheet (zero debt, strong liquidity) provides a cushion for future growth.